Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors
Authors
Keywords
Survivin, EMD640744, Cancer vaccines, Cancer immunotherapy
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 63, Issue 4, Pages 381-394
Publisher
Springer Nature
Online
2014-02-01
DOI
10.1007/s00262-013-1516-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion
- (2013) Yared Hailemichael et al. NATURE MEDICINE
- Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma
- (2012) Jürgen C. Becker et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
- (2012) Eva Ellebaek et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- T Cell Assays and MIATA: The Essential Minimum for Maximum Impact
- (2012) C.M. Britten et al. IMMUNITY
- Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients
- (2011) Hidekazu Kameshima et al. CANCER SCIENCE
- Induction of HLA-DP4–Restricted Anti-Survivin Th1 and Th2 Responses Using an Artificial Antigen-Presenting Cell
- (2011) Makito Tanaka et al. CLINICAL CANCER RESEARCH
- Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients
- (2011) Melanie Widenmeyer et al. INTERNATIONAL JOURNAL OF CANCER
- A methodological framework to enhance the clinical success of cancer immunotherapy
- (2011) Axel Hoos et al. NATURE BIOTECHNOLOGY
- Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals
- (2011) Chantale Bernatchez et al. VACCINE
- Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma
- (2010) A. P. Rapoport et al. BLOOD
- Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer
- (2010) Akihiro Miyazaki et al. CANCER SCIENCE
- MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors
- (2010) Matthias Leisegang et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer
- (2009) Ichiya Honma et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals
- (2008) Vaios Karanikas et al. CLINICAL IMMUNOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma
- (2008) Annika Berntsen et al. JOURNAL OF IMMUNOTHERAPY
- Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer
- (2008) Tetsuhiro Tsuruma et al. Journal of Translational Medicine
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started